Bli medlem
Bli medlem

Du är här


Changes in PledPharma’s Board of Directors and committees

PledPharma AB (STO: PLED) today announced that Marie Ekström Trägårdh has chosen to step down from the company's Board of Directors due to private reasons.

The duties and responsibilities of the Remuneration Committee and the Audit Committee will from now be taken on by the Board of Directors. Members of both these committees consisted previously of Håkan Åström, Chairman of the Board, and Marie Ekström Trägårdh.


Nicklas Westerholm, CEO, phone: +46 73 354 20 62

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see


Styrelsemedlem ENG Final

Författare PledPharma

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.